HuGE Literature Finder
Records
1
-
30
| Bone marrow megakaryocytic activation predicts fibrotic evolution of Philadelphia-negative myeloproliferative neoplasms. Haematologica 2020 11 . Schino Mattia, Fiorentino Vincenzo, Rossi Elena, Betti Silvia, Di Cecca Monica, Ranucci Valentina, Chiusolo Patrizia, Martini Maurizio, De Stefano Valerio, Larocca Luigi Mar |
| Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations. The American journal of surgical pathology 2018 Mar . Deniz Gur, Loghavi Sanam, Garcia-Manero Guillermo, Routbort Mark, Kanagal-Shamanna Rashmi, Quesada Andres, Khogeer Haitham, Pierce Sherry, Medeiros L Jeffrey, Kantarjian Hagop, Khoury Joseph |
| Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms. International journal of hematology 2018 Feb . Misawa Kyohei, Yasuda Hajime, Araki Marito, Ochiai Tomonori, Morishita Soji, Shirane Shuichi, Edahiro Yoko, Gotoh Akihiko, Ohsaka Akimichi, Komatsu Nor |
| Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms. Leukemia research 2018 Jan 65 42-48. Gángó Ambrus, Mózes Réka, Boha Zsófia, Kajtár Béla, Timár Botond, Király Péter Attila, Kiss Richárd, Fésüs Viktória, Nagy Noémi, Demeter Judit, Körösmezey Gábor, Borbényi Zita, Marton Imelda, Sz?ke Anita, Masszi Tamás, Farkas Péter, Várkonyi Judit, Plander Márk, Pósfai Éva, Egyed Miklós, Pál Katalin, Radványi Gáspár, Hamed Aryan, Csomor Judit, Matolcsy András, Alpár Donát, Bödör Csa |
| Effect of CALR and JAK2 mutations on the clinical and hematological phenotypes of the disease in patients with myelofibrosis - long-term experience from a single center. Neoplasma 2018 65 (2): 296-303. Palova M, Szotkowski T, Hlusi A, Indrak K, Navratilova J, Divoka M, Papajik |
| Prevalence of MPL (W515K/L) Mutations in Patients with Negative-JAK2 (V617F) Myeloproliferative Neoplasm in North-East of Iran. Iranian journal of pathology 2018 13 (4): 397-402. Shams Seyyede Fatemeh, Ayatollahi Hossein, Sadeghian Mohammad Hadi, Afzalaghaee Monavar, Shakeri Sepideh, Yazdandoust Ehsan, Sheikhi Maryam, Amini Nafiseh, Bakhshi Samane, Bahrami Afsa |
| Bone marrow fibrosis in chronic myelomonocytic leukemia is associated with increased megakaryopoiesis, splenomegaly and with a shorter median time to disease progression. Oncotarget 2017 Nov 8 (61): 103274-103282. Petrova-Drus Kseniya, Chiu April, Margolskee Elizabeth, Barouk-Fox Sharon, Geyer Julia, Dogan Ahmet, Orazi Attil |
| Primary myelofibrosis: Older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease. Leukemia research 2017 Jun 60 18-23. Barosi Giovanni, Massa Margherita, Campanelli Rita, Fois Gabriela, Catarsi Paolo, Viarengo Gianluca, Villani Laura, Poletto Valentina, Bosoni Tiziana, Magrini Umberto, Gale Robert P, Rosti Vittor |
| Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2 mutations and laboratory findings: a meta-analysis. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2017 Feb . Saki N, Shirzad R, Rahim F, Saki Malehi |
| The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia. American journal of hematology 2017 Feb . Mudireddy Mythri, Barraco Daniela, Hanson Curtis A, Pardanani Animesh, Gangat Naseema, Tefferi Ayal |
| Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations. Annals of hematology 2016 Dec . Lekovic Danijela, Gotic Mirjana, Skoda Radek, Beleslin-Cokic Bojana, Milic Natasa, Mitrovic-Ajtic Olivera, Nienhold Ronny, Sefer Dijana, Suboticki Tijana, Buac Marijana, Markovic Dragana, Diklic Milos, Cokic Vladan |
| Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis. Annals of hematology 2016 Jul . Pei Yu-Qing, Wu Yue, Wang Fei, Cui W |
| Disease characteristics and outcomes in younger adults with primary and secondary myelofibrosis. British journal of haematology 2016 Jun . Beauverd Yan, Alimam Samah, McLornan Donal P, Radia Deepti H, Harrison Claire |
| Determination of prognosis of Philadelphia chromosome-negative myeloproliferative neoplasms with a simple clinical examination: Retrospective analysis of 71 patients in a single institution. Molecular and clinical oncology 2016 Jan 4 (1): 51-57. Ito Shinichi, Tsutsumi Yutaka, Ohigashi Hiroyuki, Shiratori Souichi, Teshima Takano |
| Incidence and risk factors for myelofibrotic transformation among 272 Chinese patients with JAK2-mutated polycythemia vera. American journal of hematology 2015 Sep . Bai Jie, Ai Limei, Zhang Lei, Yang Fengchun, Zhou Yuan, Xue Yanpi |
| Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis. Turkish journal of haematology : official journal of Turkish Society of Haematology 2015 Apr . Yönal Ipek, Da?lar Aday Aynur, Akadam Teker Ba?ak, Ceylan Y?lmaz, Nalcac? Meliha, Yavuz Akif Selim, Sarg?n Fatma Den |
| The Burden of JAK2V617F Mutated Allele in Turkish Patients With Myeloproliferative Neoplasms. Journal of clinical medicine research 2015 Mar 7 (3): 161-70. Yonal-Hindilerden Ipek, Daglar-Aday Aynur, Akadam-Teker Basak, Yilmaz Ceylan, Nalcaci Meliha, Yavuz Akif Selim, Sargin Den |
| CALR mutation screening in pediatric primary myelofibrosis. Pediatric blood & cancer 2014 Dec 61 (12): 2256-62. An Wenbin, Wan Yang, Guo Ye, Chen Xiaojuan, Ren Yuanyuan, Zhang Jingliao, Chang Lixian, Wei Wei, Zhang Peihong, Zhu Xiaof |
| Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood 2014 Apr 123 (14): 2157-60. Guglielmelli Paola, Biamonte Flavia, Rotunno Giada, Artusi Valentina, Artuso Lucia, Bernardis Isabella, Tenedini Elena, Pieri Lisa, Paoli Chiara, Mannarelli Carmela, Fjerza Rajmonda, Rumi Elisa, Stalbovskaya Viktoriya, Squires Matthew, Cazzola Mario, Manfredini Rossella, Harrison Claire, Tagliafico Enrico, Vannucchi Alessandro M, , |
| JAK2 mutation: an aid in the diagnosis of occult myeloproliferative neoplasms in patients with major intraabdominal vein thrombosis and normal blood counts. The Israel Medical Association journal : IMAJ 2013 Nov 15 (11): 698-700. Sarid Nadav, Eshel Rinat, Rahamim Einam, Carmiel Michal, Kirgner Ilya, Shpringer Meirav, Trestman Svetlana, Marilus Rafi, Perry Chava, Polliack Aaron, Naparstek Ella, Herishanu Ya |
| Molecular characterization of Ph-negative myeloproliferative neoplasms in Ukraine. Experimental oncology 2013 Sep 35 (3): 202-6. Mishcheniuk O Y, Kostukevich O M, Dmytrenko I V, Sholoyko V V, Prokopenko I M, Martina Z V, Pilipenko G V, Klymenko S |
| [Detection and clinical significance of JAK2 V617F mutation in Chinese and Uyghur patients with chronic myeloproliferative in Xinjiang]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2012 Dec 33 (12): 12. Zhang XY, Maimaitili Y, Li Y, An L, Mao M, Fu L, Baier M, Wang XM |
| JAK2V617F allele burden is associated with transformation to myelofibrosis. Leukemia & lymphoma 2012 Nov 53 (11): 2210-3. Koren-Michowitz Maya, Landman Joseph, Cohen Yoram, Rahimi-Levene Naomi, Salomon Ophira, Michael Maria, Amariglio Ninette, Nagler Arn |
| [Clinical significance of the quantification of JAK2V617F allele burden in classical Ph-negative myeloproliferative neoplasms]. Medicina clínica 2012 Oct 139 (9): 373-8. Kerguelén Fuentes Ana Esther, Hernández-Maraver Dolores, Lombardia Luis, Canales Albendea Miguel Angel, Rodriguez de la Rúa A |
| Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera. Molecular biology reports 2012 Sep 39 (9): 8663-7. Karkucak Mutlu, Yakut Tahsin, Ozkocaman Vildan, Ozkalemkas Fahir, Ali Ridvan, Bayram Murat, Gorukmez Orhan, Ocakoglu Gokh |
| JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms. Collegium antropologicum 2012 Sep 36 (3): 859-65. Duleti? Antica Nacinovi?, Dekani? Andrea, Hadzisejdi? Ita, Kusen Ivona, Matusan-Ilijas Koviljka, Grohovac Dragana, Grahovac Blazenka, Jonji? Niv |
| Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis. Journal of hematology & oncology 2012 5 (1): 2. Tognon Raquel, Gasparotto Elainy P L, Neves Renata P, Nunes Natália S, Ferreira Aline F, Palma Patrícia V B, Kashima Simone, Covas Dimas T, Santana Mary, Souto Elizabeth X, Zanichelli Maria Aparecida, Simões Belinda P, de Souza Ana Maria, Castro Fabíola |
| The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population. BMC medical genetics 2012 13 (1): 6. Ohyashiki Junko H, Yoneta Masayuki, Hisatomi Hisashi, Iwabuchi Tamiko, Umezu Tomohiro, Ohyashiki Kazu |
| JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. Leukemia research 2011 Feb 35 (2): 177-82. Silver Richard T, Vandris Katherine, Wang Y Lynn, Adriano Fernando, Jones Amy V, Christos Paul J, Cross Nicholas C |
| Correlation of JAK2 V617F mutant allele quantitation with clinical presentation and type of chronic myeloproliferative neoplasm. Annals of clinical and laboratory science 2009 39 (4): 345-50. Malysz Jozef, Crisan Domni |
- Page last reviewed:Oct 1, 2021
- Page last updated:Dec 06, 2021
- Content source: